Revvity Tops Q2 Estimates, Lifts Full-Year Outlook, and Unveils $200M China Divestiture
RVTY sits 42% above its 52-week low of $81.22.
Summary
Revvity posted Q2 2026 adjusted EPS of $1.41 on revenue of $730M, beating estimates, raised its full-year guidance, and announced a definitive agreement to divest its China Immunodiagnostics business for up to $200M.
Key Events · Earnings and Guidance · RVTY
-
Q2 Earnings Beat
Adjusted EPS rose to $1.41 from $1.18 a year ago, on revenue of $730M, with pro forma organic revenue growth of 3%.
-
Full-Year Guidance Raised
Pro forma adjusted EPS is now expected at $5.30–$5.40, up from the prior implied ~$5.20, on revenue of $2.83–$2.86B.
-
China IDX Divestiture
A definitive agreement has been signed to sell the China Immunodiagnostics business for up to $200M, with closing anticipated by the end of 2027.
-
Portfolio Sharpening
The divestiture removes roughly 6% of 2025 revenue but concentrates the portfolio on higher-growth diagnostics and life sciences.
Analysis · RVTY · Industrial Applications And Services
A strong second quarter saw adjusted EPS climb to $1.41 from $1.18 a year ago, with revenue reaching $730M and comfortably exceeding expectations. Bolstered by this performance, management raised its full-year 2026 guidance—pro forma adjusted EPS is now projected at $5.30–$5.40 on revenue of $2.83–$2.86 billion. In a separate strategic move, the company signed a definitive agreement to sell its China Immunodiagnostics business for up to $200 million, a transaction expected to close by the end of 2027. While the divestiture removes a 6% revenue contributor, it sharpens the focus on higher-growth areas. Together, the earnings beat, upgraded guidance, and portfolio-shaping sale signal strong operational momentum and a clearer growth trajectory.
At the time of this filing, RVTY was trading at $115.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $81.22 to $118.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.